NCT00988949 - Proof Of Mechanism Study To Determine Efficacy Of PF-04455242 In Blocking Spiradoline (PF-00345768) Stimulated Prolactin Release | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions

Bipolar Depression

Interventions

DRUG

PF-04455242

Single oral 18 mg dose of PF-04455242.

DRUG

spiradoline

Spiradoline 3.2 mcg/kg to be administered intramuscularly once on the morning of the spiradoline challenge day.

OTHER

Placebo

Oral placebo.

DRUG

spiradoline

Spiradoline 3.2 mcg/kg to be administered intramuscularly once on the morning of the spiradoline challenge day.

DRUG

PF-04455242

Single 30 mg oral dose of PF-04455242.

DRUG

spiradoline

Spiradoline 3.2 mcg/kg to be administered intramuscularly once on the morning of the spiradoline challenge day.

Trial Locations (1)

Pfizer Investigational Site, Singapore